XORTX Therapeutics Files December 2024 Report
Ticker: XRTX · Form: 6-K · Filed: Dec 12, 2024 · CIK: 1729214
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
XORTX files 6-K for Dec 2024, CEO Davidoff signs off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on December 12, 2024, to report its activities for the month of December 2024. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing provides an update on XORTX Therapeutics' regulatory reporting status and confirms their adherence to SEC requirements for foreign private issuers.
Risk Assessment
Risk Level: low — This is a routine filing confirming the company's reporting status and is not indicative of new financial or operational risks.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- December 12, 2024 (date) — Filing date
FAQ
What type of report is XORTX Therapeutics Inc. filing?
XORTX Therapeutics Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
Which SEC form will XORTX Therapeutics Inc. use for its annual reports?
XORTX Therapeutics Inc. will file its annual reports under cover of Form 20-F.
Who signed the Form 6-K filing on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, the Chief Executive Officer, signed the Form 6-K filing.
On what date was this Form 6-K filed?
This Form 6-K was filed on December 12, 2024.
What is the business address of XORTX Therapeutics Inc. listed in the filing?
The business address listed is Suite 2400 - 745 Thurlow Street, Vancouver, A1, V6E 0C5.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-12-12 10:19:23
Filing Documents
- f6k_121224.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-006897.txt ( ) — 15KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: December 12, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Press Release dated December 12, 2024